Identification of small-molecule inhibitors of Yersinia pestis type III secretion system YscN atpase

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Swietnicki, Wieslaw ^a   Carmany, Daniel ^b   Retford, Michael ^c   Guelta, Mark ^c   Dorsey, Russell ^c   Bozue, Joel ^d   Lee, Michael S ^d   Olson, Mark A ^d  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c EDGEWOOD CHEMICAL BIOLOGICAL CENTER   (United States)

^d UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DIMETHYL SULFOXIDE; EGTAZIC ACID; ENZYME INHIBITOR; METHANOL; UNCLASSIFIED DRUG; YERSINIA OUTER PROTEIN E; YERSINIA SECRETION CHAPERONE N PROTEIN; ADENOSINE TRIPHOSPHATE; BACTERIAL PROTEIN; CARRIER PROTEIN; HYBRID PROTEIN; MALTOSE BINDING PROTEIN; YSCN PROTEIN, YERSINIA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CATALYSIS; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME RELEASE; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MAMMAL CELL; MOUSE; NONHUMAN; PLAGUE; PROTEIN DOMAIN; PROTEIN TARGETING; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; TYPE III SECRETION SYSTEM; VALIDATION PROCESS; YERSINIA PESTIS; YERSINIA SECRETION CHAPERONE N GENE; ANIMAL; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HELA CELL; HYDROLYSIS; KINETICS; METABOLISM; MICROBIOLOGY; MOLECULAR LIBRARY; PATHOGENICITY; PROTEIN MULTIMERIZATION; SECRETION; SEQUENCE HOMOLOGY;

ANIMALIA; BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA MALLEI; MAMMALIA; NEGIBACTERIA; SALMONELLA TYPHIMURIUM; SHIGELLA FLEXNERI; YERSINIA PESTIS;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANIMALS; BACTERIAL PROTEINS; BURKHOLDERIA MALLEI; CARRIER PROTEINS; CATALYTIC DOMAIN; CELL DEATH; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE DELETION; GENES, BACTERIAL; HELA CELLS; HUMANS; HYDROLYSIS; INHIBITORY CONCENTRATION 50; KINETICS; MALTOSE-BINDING PROTEINS; MICE; MODELS, MOLECULAR; PLAGUE; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SMALL MOLECULE LIBRARIES; YERSINIA PESTIS;

EID: 79956211337     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019716     Document Type: Article

References (65)

1. Butler T, (2009) Plague into the 21st century. Clin Infect Dis 49: 736-742.
2. Veenendaal AK, Sundin C, Blocker AJ, (2009) Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191: 563-570.
3. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR, et al. (2008) An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4: 325-336.
4. Kline T, Felise HB, Barry KC, Jackson SR, Nguyen HV, et al. (2008) Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J Med Chem 51: 7065-7074.
5. Tree JJ, Wang D, McInally C, Mahajan A, Layton A, et al. (2009) Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun 77: 4209-4220.
6. Dahlgren MK, Kauppi AM, Olsson IM, Linusson A, Elofsson M, (2007) Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides-potent inhibitors of type III secretion in Yersinia. J Med Chem 50: 6177-6188.
7. Tautz L, Bruckner S, Sareth S, Alonso A, Bogetz J, et al. (2005) Inhibition of Yersinia tyrosine phosphatase by furanyl salicylate compounds. J Biol Chem 280: 9400-9408.
8. Kim OK, Garrity-Ryan LK, Bartlett VJ, Grier MC, Verma AK, et al. (2009) N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents. J Med Chem 52: 5626-5634.
9. Pan NJ, Brady MJ, Leong JM, Goguen JD, (2009) Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 53: 385-392.
10. Yuk MH, Harvill ET, Miller JF, (1998) The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol Microbiol 28: 945-959.
11. Cornelis GR, Boland A, Boyd AP, Geuijen C, Iriarte M, et al. (1998) The virulence plasmid of Yersinia, an antihost genome. Microbiol Mol Biol Rev 62: 1315-1352.
12. Journet L, Hughes KT, Cornelis GR, (2005) Type III secretion: a secretory pathway serving both motility and virulence (review). Mol Membr Biol 22: 41-50.
13. Cornelis GR, Van Gijsegem F, (2000) Assembly and function of type III secretory systems. Annu Rev Microbiol 54: 735-774.
14. Pujol C, Bliska JB, (2003) The ability to replicate in macrophages is conserved between Yersinia pestis and Yersinia pseudotuberculosis. Infect Immun 71: 5892-5899.
15. Pujol C, Bliska JB, (2005) Turning Yersinia pathogenesis outside in: subversion of macrophage function by intracellular yersiniae. Clin Immunol 114: 216-226.
16. Neyt C, Cornelis GR, (1999) Insertion of a Yop translocation pore into the macrophage plasma membrane by Yersinia enterocolitica: requirement for translocators YopB and YopD, but not LcrG. Mol Microbiol 33: 971-981.
17. Dacheux D, Goure J, Chabert J, Usson Y, Attree I, (2001) Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages. Mol Microbiol 40: 76-85.
18. Akeda Y, Galan JE, (2005) Chaperone release and unfolding of substrates in type III secretion. Nature 437: 911-915.
19. Muller SA, Pozidis C, Stone R, Meesters C, Chami M, et al. (2006) Double hexameric ring assembly of the type III protein translocase ATPase HrcN. Mol Microbiol 61: 119-125.
20. Moraes TF, Spreter T, Strynadka NC, (2008) Piecing together the type III injectisome of bacterial pathogens. Curr Opin Struct Biol 18: 258-266.
21. Akeda Y, Galan JE, (2004) Genetic analysis of the Salmonella enterica type III secretion-associated ATPase InvC defines discrete functional domains. J Bacteriol 186: 2402-2412.
22. Paul K, Erhardt M, Hirano T, Blair DF, Hughes KT, (2008) Energy source of flagellar type III secretion. Nature 451: 489-492.
23. Ritchie JM, Waldor MK, (2005) The locus of enterocyte effacement-encoded effector proteins all promote enterohemorrhagic Escherichia coli pathogenicity in infant rabbits. Infect Immun 73: 1466-1474.
24. Woestyn S, Allaoui A, Wattiau P, Cornelis GR, (1994) YscN, the putative energizer of the Yersinia Yop secretion machinery. J Bacteriol 176: 1561-1569.
25. Ulrich RL, DeShazer D, (2004) Type III secretion: a virulence factor delivery system essential for the pathogenicity of Burkholderia mallei. Infect Immun 72: 1150-1154.
26. Whitlock GC, Estes DM, Torres AG, (2007) Glanders: off to the races with Burkholderia mallei. FEMS Microbiol Lett 277: 115-122.
27. Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, et al. (2007) Type VI secretion is a major virulence determinant in Burkholderia mallei. Mol Microbiol 64: 1466-1485.
28. Zarivach R, Vuckovic M, Deng W, Finlay BB, Strynadka NC, (2007) Structural analysis of a prototypical ATPase from the type III secretion system. Nat Struct Mol Biol 14: 131-137.
29. Ferber DM, Brubaker RR, (1981) Plasmids in Yersinia pestis. Infect Immun 31: 839-841.
30. Worsham PL, Stein MP, Welkos SL, (1995) Construction of defined F1 negative mutants of virulent Yersinia pestis. Contrib Microbiol Immunol 13: 325-328.
31. De Marcos Lousa C, Dietrich D, Johnson B, Baldwin SA, Holdsworth MJ, et al. (2009) The NBDs that wouldn't die: A cautionary tale of the use of isolated nucleotide binding domains of ABC transporters. Commun Integr Biol 2: 97-99.
32. Motre A, Li Y, Kong H, (2008) Enhancing helicase-dependent amplification by fusing the helicase with the DNA polymerase. Gene 420: 17-22.
33. Ding C, Urabe M, Bergoin M, Kotin RM, (2002) Biochemical characterization of Junonia coenia densovirus nonstructural protein NS-1. J Virol 76: 338-345.
34. Andrade A, Pardo JP, Espinosa N, Perez-Hernandez G, Gonzalez-Pedrajo B, (2007) Enzymatic characterization of the enteropathogenic Escherichia coli type III secretion ATPase EscN. Arch Biochem Biophys 468: 121-127.
35. Blaylock B, Riordan KE, Missiakas DM, Schneewind O, (2006) Characterization of the Yersinia enterocolitica type III secretion ATPase YscN and its regulator, YscL. J Bacteriol 188: 3525-3534.
36. Irwin JJ, Shoichet BK, (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45: 177-182.
37. Keyser P, Elofsson M, Rosell S, Wolf-Watz H, (2008) Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Intern Med 264: 17-29.
38. Chen ZW, Hsuan SL, Liao JW, Chen TH, Wu CM, et al. (2010) Mutations in the Salmonella enterica serovar Choleraesuis cAMP-receptor protein gene lead to functional defects in the SPI-1 Type III secretion system. Vet Res 41: 5.
39. Endoh T, Engel JN, (2009) CbpA: a polarly localized novel cyclic AMP-binding protein in Pseudomonas aeruginosa. J Bacteriol 191: 7193-7205.
40. Smith RS, Wolfgang MC, Lory S, (2004) An adenylate cyclase-controlled signaling network regulates Pseudomonas aeruginosa virulence in a mouse model of acute pneumonia. Infect Immun 72: 1677-1684.
41. Riordan KE, Schneewind O, (2008) YscU cleavage and the assembly of Yersinia type III secretion machine complexes. Mol Microbiol 68: 1485-1501.
42. Cornelis GR, (2002) The Yersinia Ysc-Yop 'type III' weaponry. Nat Rev Mol Cell Biol 3: 742-752.
43. Yin JX, Geater A, Chongsuvivatwong V, Dong XQ, Du CH, et al. (2008) Predictors for presence and abundance of small mammals in households of villages endemic for commensal rodent plague in Yunnan Province, China. BMC Ecol 8: 18.
44. Rocke TE, Smith SR, Stinchcomb DT, Osorio JE, (2008) Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits. J Wildl Dis 44: 930-937.
45. Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, et al. (1997) Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337: 677-680.
46. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, et al. (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46: 155-164.
47. Martin CA, Hoven AD, Cook AM, (2008) Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing. Eur J Clin Microbiol Infect Dis 27: 635-642.
48. Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL, et al. (2005) Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother 49: 4101-4109.
49. Iwatsuki M, Uchida R, Yoshijima H, Ui H, Shiomi K, et al. (2008) Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. II: physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 61: 230-236.
50. Iwatsuki M, Uchida R, Yoshijima H, Ui H, Shiomi K, et al. (2008) Guadinomines, Type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo) 61: 222-229.
51. Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP, et al. (2010) Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother 54: 1988-1999.
52. Harmon DE, Davis AJ, Castillo C, Mecsas J, (2010) Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis. Antimicrob Agents Chemother 54: 3241-3254.
53. Worsham P, Hunter M, (1998) Characterization of pestoides F, an atypical strain of Y. pestis. Medische Microbiologie 6: S34-S35.
54. Pitt ML, (2004) Animal Models and Correlates of Protection for Plague Vaccines Workshop, Gaithersburg, MD, 13-14 October, 2004.
55. Conchas RF, Carniel E, (1990) A highly efficient electroporation system for transformation of Yersinia. Gene 87: 133-137.
56. Kaniga K, Delor I, Cornelis GR, (1991) A wide-host-range suicide vector for improving reverse genetics in gram-negative bacteria: inactivation of the blaA gene of Yersinia enterocolitica. Gene 109: 137-141.
57. Surgalla MJ, Beesley ED, (1969) Congo red-agar plating medium for detecting pigmentation in Pasteurella pestis. Appl Microbiol 18: 834-837.
58. Anderson GW Jr, Leary SE, Williamson ED, Titball RW, Welkos SL, et al. (1996) Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and-negative strains of Yersinia pestis. Infect Immun 64: 4580-4585.
59. Kelley LA, Sternberg MJ, (2009) Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 4: 363-371.
60. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminatham SM, et al. (1983) CHARMm: a program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 4: 187-217.
61. Jiang X, Kumar K, Hu X, Wallqvist A, Reifman J, (2008) DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0. Chem Cent J 2: 18.
62. Huey R, Morris GM, Olson AJ, Goodsell DS, (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28: 1145-1152.
63. Halgren TA, (1998) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17: 490-519.
64. Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M, (2005) LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 23.
65. Lloyd SA, Norman M, Rosqvist R, Wolf-Watz H, (2001) Yersinia YopE is targeted for type III secretion by N-terminal, not mRNA, signals. Mol Microbiol 39: 520-531.